Drug
Teclistamab clinical trials
Also written JNJ-64007957 and Tecvayli.
- studies test it
- 47
- open now
- 31
- in phase 3
- 9
- first study started
- 2017
Keep track of what changes. Save the teclistamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
42 studies that test it; most in 2025 (12); 5 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 12 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 29
- Phase 3
- 9
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 35
Janssen Research & Development, LLC (10) · National Cancer Institute (NCI) (5) · European Myeloma Network B.V. (3) · University of Heidelberg Medical Center (2) · Peking Union Medical College Hospital (2) · Johnson & Johnson Private Limited (1) · Multiple Myeloma Research Consortium (1) · PETHEMA Foundation (1)
Often tested with
Tested in the same studies.
Talquetamab (14) · Pomalidomide (4) · Dexamethasone (3) · Bortezomib (3) · Lenalidomide (3) · Immune Checkpoint Inhibitors (1) · Teclistamab Regimen (1) · Daratumumab (1)
Studies
Open first, then newest update. How each study uses teclistamab is read from its arms, and is right about nine times in ten.
Testing it · 47
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingPhase 2National Cancer Institute (NCI)NCT06948084Written as Teclistamab
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as Teclistamab
- Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaRecruitingPhase 1National Cancer Institute (NCI)NCT06465316Written as Teclistamab
- Testing the Effect of Teclistamab on Recurrent Plasmablastic LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT07332507Written as Teclistamab
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentRecruitingPhase 1/2National Cancer Institute (NCI)NCT07463807Written as Teclistamab
- A Study of Teclistamab and Mezigdomide in People With Multiple MyelomaRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07105059Written as Teclistamab
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingPhase 3European Myeloma Network B.V.NCT05243797Written as Teclistamab
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as Teclistamab
- Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaRecruitingPhase 2Naresh BummaNCT07657312Written as Teclistamab
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT05552222Written as Teclistamab
- Teclistamab In Waldenstrom's MacroglobulinemiaNot yet recruitingPhase 2Massachusetts General HospitalNCT07791498Written as Teclistamab
- Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.Not yet recruitingPhase 2Odense University HospitalNCT07757412Written as Teclistamab (Tec) and Pomalidomide (Pom)
- A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).RecruitingPhase 2Shanghai Zhongshan HospitalNCT07638683Written as Teclistamab
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingPhase 3Polish Myeloma ConsortiumNCT07740486Written as Teclistamab
- Immuno-PRISM (PRecision Intervention Smoldering Myeloma)RecruitingPhase 2Irene Ghobrial, MDNCT05469893Written as Teclistamab
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingPhase 3University of LeedsNCT07649525Written as Teclistamab
- Teclistamab-Daratumumab in AL AmyloidosisRecruitingPhase 2Rajshekhar Chakraborty, MDNCT07110844Written as Teclistamab
- GMMG-HD11/DSMM XXI/64007957MMY3010Not yet recruitingPhase 3University of Heidelberg Medical CenterNCT07671287Written as Teclistamab
- Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5Not yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07631208Written as Teclistamab(SC)
- Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)RecruitingPhase 2Noffar BarNCT06993675Written as Teclistamab
See all 47 studies that test teclistamab →
Given in every arm · 6 — teclistamab is usual care beside what is tested
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as Teclistamab
- Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple MyelomaRecruitingPhase 1Christopher StrouseNCT07581704Written as Teclistamab
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04722146Written as Teclistamab
- Study of Teclistamab in Combination in Elderly Patients With Multiple MyelomaActive, not recruitingPhase 2University Hospital, LilleNCT05572229Written as Teclistamab
- A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04108195Written as Teclistamab
- Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2Nantes University HospitalNCT06353022Written as Teclistamab
As the comparator · 3 — what is tested is compared with teclistamab
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT07518186Written as Teclistamab
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT07258511Written as Teclistamab
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3AbbVieNCT07728188Written as Teclistamab
Codes
What other systems call teclistamab · ClinicalTrials.gg INT002161
- MeSH (NLM) C000731928teclistamabOne source NLM
- UNII (FDA) 54534MX6Z9TECLISTAMABConfirmed FDA, NLM, Wikidata
- RxNorm 2619426One source FDA
- Wikidata Q113366205teclistamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C136823TeclistamabOne source FDA
- DrugBank DB16655One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731928 | teclistamab | One source NLM |
| UNII (FDA) | 54534MX6Z9 | TECLISTAMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2619426 | — | One source FDA |
| Wikidata | Q113366205 | teclistamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C136823 | Teclistamab | One source FDA |
| DrugBank | DB16655 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.